Androgen-deprivation therapy and cardiovascular harm: Let's not throw out the baby with the bathwater

European Urology

Volumn 65, Issue 4, 2014, Pages 710-712

  Nguyen, Paul L ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; GONADORELIN AGONIST; TESTOSTERONE; TRIACYLGLYCEROL;

ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; DIABETES MELLITUS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GLEASON SCORE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; ISCHEMIC HEART DISEASE; MEDICARE; META ANALYSIS (TOPIC); MICROMETASTASIS; ORCHIECTOMY; PRIORITY JOURNAL; PROPENSITY SCORE; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SUDDEN CARDIAC DEATH; TESTOSTERONE BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL;

ANDROGEN ANTAGONISTS; GONADOTROPIN-RELEASING HORMONE; HUMANS; MALE; MYOCARDIAL INFARCTION; ORCHIECTOMY; PROSTATIC NEOPLASMS; STROKE;

EID: 84894490804     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2013.03.002     Document Type: Editorial

References (10)

1. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
2. A.V. D'Amico, J.W. Denham, and J. Crook et al. Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions J Clin Oncol 25 2007 2420 2425
3. G.N. Levine, A.V. D'Amico, and P. Berger et al. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology Circulation 121 2010 833 840
4. FDA drug safety communication: update to ongoing safety review of GnRH agonists and notification to manufacturers of GnRH agonists to add new safety information to labeling regarding increased risk of diabetes and certain cardiovascular diseases. US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ucm229986.htm. Released October 20, 2010. Accessed Auguest 17, 2011.
5. C.G. Jespersen, M. Nørgaard, and M. Borre Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population based cohort study Eur Urol 65 2014 704 709
6. P.L. Nguyen, Y. Je, and F.A. Schutz et al. Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials JAMA 306 2011 2359 2366
7. A.V. D'Amico, M.H. Chen, and A.A. Renshaw et al. Androgen suppression and radiation compared with radiation alone for prostate cancer: a randomized trial JAMA 299 2008 289 295
8. A. Nanda, M.H. Chen, and M.H. Braccioforte et al. Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction JAMA 302 2009 866 873
9. P.J. Saylor, and M.R. Smith Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer J Natl Compr Canc Netw 8 2010 211 223
10. P.L. Nguyen, M.H. Chen, and J.A. Beckman et al. Influence of androgen deprivation therapy on all-cause mortality in men with high-risk prostate cancer and a history of congestive heart failure or myocardial infarction Int J Radiat Oncol Biol Phys 82 2012 1411 1416